Virbac stock holds near its yearly low as margins improve

Published on 09/23/2026 at 11:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac stock closed at EUR 307.50 on September 21, 2026, 21.05 percent below its yearly high. First-half profit rose 5.9 percent to EUR 87.1 million.

Modernes Pharmawerk für Tiergesundheit in sonniger südfranzösischer Landschaft — Fotorealistische Aufnahme zeigt Veterinärpharma-Anlage von Virbac S.A., passend zu ISIN FR0000031577, moderner Standort Südfrankreich, Illustration mit AI erstellt.

Virbac stock (ISIN FR0000031577) closed at EUR 307.50 on Euronext Paris on September 21, 2026, 10.50 euros above its 52-week low of EUR 297.00 and EUR 82.00 below its high of EUR 389.50. The veterinary pharmaceutical group enters September 23, 2026, with operating progress in its latest reported period but a share price still 13.99 percent below its year-to-date starting level.

Half-year margin reaches 18.8 percent

According to Investir Les Echos on September 22, 2026, Virbac increased first-half 2026 revenue by 7.4 percent on an organic basis. The operating margin reached 18.8 percent, 50 basis points above the comparable period, while consolidated net profit rose 5.9 percent to EUR 87.1 million.

The operating figures show why the company retained its full-year framework. Companion-animal sales increased 10 percent in the first half of 2026, while livestock-animal sales rose 6.7 percent, according to Investir Les Echos.

Guidance demands a stronger second half

Virbac is targeting the upper end of its fiscal-year 2026 organic revenue-growth range of 5.5 percent to 7.5 percent at constant scope and exchange rates. Zonebourse reported on September 22, 2026, that adjusted current operating profit is expected to reach about 17 percent of revenue in fiscal year 2026.

That target implies more than 100 basis points of margin improvement in the second half of 2026, compared with the 50 basis points delivered in the first half. For investors, the key test is therefore not only revenue growth but whether the company can convert the upper-end sales outlook into the stated full-year profitability level.

Stock remains 21.05 percent below high

The September 21, 2026 closing price of EUR 307.50 leaves Virbac 21.05 percent below its 52-week high of EUR 389.50 and close to the lower end of the EUR 297.00 to EUR 389.50 yearly range. The same market snapshot recorded a 2.38 percent decline over 52 weeks, while the stock was down 13.99 percent year to date.

Virbac stock closed at EUR 307.50 on Euronext Paris on September 21, 2026. The price was EUR 10.50 above the 52-week low and EUR 82.00 below the 52-week high, keeping the market valuation sensitive to evidence that the 17 percent operating-profit target can be delivered.